MARKET

AMLX

AMLX

Amylyx Pharmaceuticals
NASDAQ
17.96
-0.74
-3.96%
After Hours: 17.96 0 0.00% 17:55 06/30 EDT
OPEN
18.79
PREV CLOSE
18.70
HIGH
19.15
LOW
17.84
VOLUME
2.88M
TURNOVER
--
52 WEEK HIGH
19.15
52 WEEK LOW
5.97
MARKET CAP
2.00B
P/E (TTM)
-11.9201
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AMLX last week (0622-0626)?
Weekly Report · 1d ago
Could Amylyx (AMLX) ALS Safety Data Quietly Reframe Its Neurodegeneration Versus Endocrine Strategy?
Simply Wall St · 3d ago
Amylyx Pharmaceuticals (AMLX) Reports Early LUMINA Safety Data, Is The Stock Still Below Fair Value?
Simply Wall St · 4d ago
Amylyx Pharmaceuticals Price Target Raised to $40.00/Share From $30.00 by Guggenheim
Dow Jones · 5d ago
Amylyx Pharmaceuticals Is Maintained at Buy by Guggenheim
Dow Jones · 5d ago
Guggenheim Maintains Buy on Amylyx Pharmaceuticals, Raises Price Target to $40
Benzinga · 5d ago
Amylyx price target raised to $40, named a Best Idea at Guggenheim
TipRanks · 5d ago
H.C. Wainwright Reaffirms Their Buy Rating on Amylyx Pharmaceuticals Inc (AMLX)
TipRanks · 6d ago
More
About AMLX
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on four investigational therapies across several diseases. Its lead investigational asset is avexitide, an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist. Avexitide has been evaluated as a treatment for Post-Bariatric Hypoglycemia (PBH) and congenital HI, two indications characterized by hyperinsulinemic hypoglycemia. In addition to avexitide, it is advancing AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol in Wolfram syndrome, AMX0114 in amyotrophic lateral sclerosis (ALS), and AMX0318 in PBH and other rare diseases. AMX0035 is designed to mitigate neurodegeneration by targeting endoplasmic reticulum stress and mitochondrial dysfunction, two cellular processes central to neuronal cell death and neurodegeneration. AMX0114 is an investigational antisense oligonucleotide and AMX0318 is a novel GLP-1 receptor antagonist.

Webull offers Amylyx Pharmaceuticals Inc stock information, including NASDAQ: AMLX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMLX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AMLX stock methods without spending real money on the virtual paper trading platform.